How Glofitamab Targets Large B-Cell Lymphoma
Glofitamab is a bispecific T-cell engager antibody that treats relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma by redirecting a patient's T cells to kill cancer cells. It binds simultaneously to CD20 on B cells (including lymphoma cells) and CD3 on T cells, triggering T-cell activation, cytokine release, and direct tumor cell lysis.[1]
Administered via subcutaneous injection after a step-up dosing to mitigate cytokine release syndrome (CRS), it engages the immune system without needing prior T-cell manipulation, unlike CAR-T therapies.[1][2]
What Happens Step-by-Step in the Body
1. Glofitamab's one arm latches onto CD20, a protein overexpressed on malignant B cells in DLBCL.
2. The other arm grips CD3 on nearby T cells, pulling them into close contact.
3. This synapse activates T cells, releasing perforin and granzymes that punch holes in the cancer cell membrane, leading to apoptosis.
4. Immune amplification occurs via cytokine signaling, drawing more T cells and amplifying the kill.[1][3]
This mechanism spares normal CD20+ B cells temporarily but depletes them over time, requiring monitoring for infections.
How It Compares to CAR-T Like Axi-Cel or Tisa-Cel
Unlike one-time CAR-T infusions, which genetically engineer patient T cells ex vivo, glofitamab is off-the-shelf and repeatable every few weeks. Phase 2 trials showed 52% overall response rates in heavily pretreated DLBCL patients, with 39% complete responses, versus 40-50% for CAR-T but with lower manufacturing failures and broader accessibility.[2][4]
| Aspect | Glofitamab | CAR-T (e.g., Axi-Cel) |
|--------|------------|-----------------------|
| Administration | SubQ, outpatient possible | IV infusion post-manufacturing |
| Response Rate (r/r DLBCL) | ~52% ORR | ~80% ORR initially |
| Onset | Days to weeks | Weeks |
| Cost Barrier | Lower upfront | High due to personalization |
Common Side Effects Patients Experience
CRS affects ~60% (mostly grade 1-2, managed with steroids/toçilizumab), neurotoxicity ~4%, infections from B-cell aplasia, and cytopenias. Step-up dosing reduces severe CRS to <5%.[1][2] Long-term, hypogammaglobulinemia risks recur.
Who Qualifies and When Is It Approved
FDA approved March 2023 for adults with relapsed/refractory LBCL after ≥2 prior lines (including CAR-T). EU approval followed in 2023. Not first-line; ongoing trials test earlier use.[1][5]
Ongoing Trials and Future Role
NP30179 (phase 3) compares glofitamab to chemo vs. lenalidomide in second-line; early data show durable remissions up to 18+ months in 43% of responders. Combinations with polatuzumab vedotin explore frontline potential.[4][6]
Sources
[1]: FDA Label - Columvi (glofitamab-gxbm)
[2]: NEJM 2023 - Glofitamab in r/r DLBCL
[3]: Genentech Mechanism Overview
[4]: ASH 2023 Abstracts - Glofitamab Updates
[5]: EMA Approval Summary
[6]: ClinicalTrials.gov - NP30179